Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021

Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1689-1697. doi: 10.1007/s10096-024-04882-z. Epub 2024 Jun 27.

Abstract

Purpose: To investigate the association of potential risk factors for urinary tract infections (UTI) caused by E. coli producing ESBL vs. not producing ESBL in Iceland.

Methods: Observational, case-control study including a cohort of 27,747 patients (22,800 females, 4,947 males; 1207 cases, 26,540 controls) of all ages with UTI caused by E. coli in 2012 to 2021 at the clinical microbiology laboratory covering about 2/3 of the Icelandic population. Clinical patient data was obtained from three national databases. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) as a measure of association between ESBL and exposure variables.

Results: The proportion of samples with ESBL-producing E. coli increased during the study period, from 2.6% in 2012 to 7.6% in 2021 (p < 0.001). ESBL-positive strains were detected in 1207 individuals (4.4%), 905 females (4.0%) and 302 males (6.1%). The following risk factors were identified: Male sex, higher age, institution type (hospital, nursing home), hospital-associated UTI, Charlson comorbidity index score ≥ 3, history of cystitis or hospitalization in the past year, and prescriptions for certain antibiotics or proton pump inhibitors (PPIs: OR 1.51) in the past half year. The antibiotic associated with the highest risk was ciprofloxacin (OR 2.45).

Conclusion: The prevalence of UTIs caused by ESBL-producing E. coli has been increasing in Iceland. The strongest risk factors for ESBL production were previous antibiotic use, especially ciprofloxacin, and previous PPI use, both considered to be overprescribed. It is important to promote the prudent use of these drugs.

Keywords: Escherichia coli; Antibiotics; Antimicrobial agents; Antimicrobial resistance; Beta-lactamases; Risk factors; Urinary tract infections.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / epidemiology
  • Escherichia coli Infections* / microbiology
  • Escherichia coli* / drug effects
  • Escherichia coli* / enzymology
  • Escherichia coli* / genetics
  • Escherichia coli* / isolation & purification
  • Female
  • Humans
  • Iceland / epidemiology
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / epidemiology
  • Urinary Tract Infections* / microbiology
  • Young Adult
  • beta-Lactamases* / metabolism

Substances

  • beta-Lactamases
  • Anti-Bacterial Agents